TY - JOUR T1 - Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis JF - In Vivo JO - In Vivo SP - 2013 LP - 2019 DO - 10.21873/invivo.11698 VL - 33 IS - 6 AU - YASUYOSHI OKAMURA AU - TOMOAKI TERAKAWA AU - MARIKO SAKAMOTO AU - YUKARI BANDO AU - KOTARO SUZUKI AU - TAKUTO HARA AU - JUNYA FURUKAWA AU - KENICHI HARADA AU - NOBUYUKI HINATA AU - YUZO NAKANO AU - MASATO FUJISAWA Y1 - 2019/11/01 UR - http://iv.iiarjournals.org/content/33/6/2013.abstract N2 - Background/ Aim: We evaluated surgical outcomes following nephrectomy and thrombectomy with and without presurgical treatment with pazopanib in patients with advanced renal cell carcinoma with inferior vena caval tumor thrombosis. Materials and Methods: We compared surgical outcomes between patients undergoing presurgical treatment with pazopanib vs. surgery-alone in 19 patients who underwent surgery for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis at the Kobe University Hospital. Results: Comparing the presurgical group with the surgery-alone group, respectively, the average operative time was 497 min vs. 627 min (p=0.08); average blood loss was 1,928 ml vs. 7,393 ml (p<0.05); average postoperative hospitalization duration was 15.3 days vs. 21.6 days (p=0.05); and the perioperative complication rate was lower (presurgical: 33% vs. surgery-alone: 50%). Conclusion: Presurgical treatment with pazopanib decreased surgical difficulty and improved surgical outcomes for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis. ER -